Bimagrumab
Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese
Eli Lilly · Phase 2 · Completed · Enrollment 507
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Placebo/30 mg/kg Bimagrumab | 9 participants | 1 participants | 10 participants | n/r | 0 |
| 10/30 mg/kg Bimagrumab | 15 participants | 5 participants | 27 participants | n/r | 0 |
| 30 mg/kg Bimagrumab | 20 participants | 7 participants | 25 participants | n/r | 0 |
| Placebo + 1.0 mg Semaglutide | 25 participants | 6 participants | 19 participants | n/r | 0 |
| Placebo + 2.4 mg Semaglutide | 26 participants | 10 participants | 21 participants | n/r | 0 |
| 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 23 participants | 6 participants | 27 participants | n/r | 0 |
| 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 34 participants | 10 participants | 29 participants | n/r | 0 |
| 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | n/r | n/r | n/r | n/r | n/r |
| 30 mg/kg Bimagrumab + 2.4 mg Semaglutide | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.